Cite this post as:
Scott Weingart, MD FCCM. EMCrit Wee – MOPETT Trial. EMCrit Blog. Published on December 11, 2012. Accessed on April 1st 2023. Available at [https://emcrit.org/emcrit/mopett-trial/ ].
Dr. Scott Weingart, Course Director, reports no relevant financial relationships with ineligible companies.
This episode’s speaker(s), (listed above), report no relevant financial relationships with ineligible companies.
Original Release: December 11, 2012
Date of Most Recent Review: Jan 1, 2022
Termination Date: Jan 1, 2025
You finished the 'cast,
Now Join EMCrit!
As a member, you can...
- Get CME hours
- Get the On Deeper Reflection Podcast
- Support the show
- Write it off on your taxes or get reimbursed by your department
Get the EMCrit Newsletter
If you enjoyed this post, you will almost certainly enjoy our others. Subscribe to our email list to keep informed on all of the Resuscitation and Critical Care goodness.
This Post was by the EMCrit Crew, published 10 years ago. We never spam; we hate spammers! Spammers probably work for the Joint Commission.
Great post, thanks. My practice has been not to lyse sub-massive PE, but your blogs and emerging evidence have changed my mind.
I *really* like LMWH for PE (1), and I’m glad to see it combined with lytics in the MOPETT trial (and your prior post with Jeff Kline). I wonder if uncontrolled yo-yo-ing of PTT with heparin drips causes more bleeding than thrombolytics.
 Cochrane Database Syst Rev 2004; CD001100. LMWH vs heparin in PE ==> LMWH reduces major hemorrhage and mortality.
agree–i think heparin may be the more dangerous drug in these cases.
Hi Scott- I just gave half strength TPA to a large PE in a young person here in New Zealand. I cannot get an urgent ultrasound at my small hospital. It was almost occluding her entire right main pulmonary artery. she was hypoxic but hemodynamically stable. She did fine but the internal medicine doctors (multiple) ripped my head off and officially complained to my ED director about me!! They said the MOPETT trial had been “discredited” because it’s results were so discordant with “other larger trials” that showed no benefit to RV on ultrasound, the best being a ” NEJM… Read more »
Great post thanks as always for the superb education.
So would you start ordering Echo’s on all PE pts to see if they meet criteria? Also where/what do you think is the optimal time to lyse, in the ED? Inpatient? clearly these are stable patients… It would also seem like we would need to get Pulmonary buy-in at our own shop before starting something like this..
Echo should be done bedside by ED doc. If you are having trouble visualizing or are not there yet with your echo skills, then any sig. sized clot should signal the need for an echo. I lyse in the ED, I think its fine to wait till ICU, but we are much more familiar with lytics and administration.
Great podcasts! My practice (probably influenced by routine bedside ultrasound – hard to ignore the pathetic little LVs crushed in a corner by massive RVs) had been to lyse patients with RV:LV ratios above 1 – they just seemed a lot sicker. It was impressive to see the RV dysfunction improve significantly almost every time. Nice to have some evidence to back it up!
yep cockroach removal, shoulder/jaw reduction, and a lysed PE are some of the most satisfying procedures in EM.
I’d add reduction of nursemaid’s elbow and catheterisation for urinary retention. Just about to half-dose a submassive PE in the next room as I type – living the podcast, Scott! Thanks for sharing, as always…
or rather moderate, not-quite-submassive…can we call it sub-submassive???
yep those are two good ones
Hey Scott- I don´t understand the inclusion criteria (and definition of “sub-massive”): 1) Thrombus on CT + 2 clinical criteria OR 2) CT + 2 clinical criteria + elevated BNP or Trop I or right heart strain on echo? My definition of “sub-massive” PE would be 2), 1) being “mild” – but I don´t seem to get it from the abstract and slides. If it´s 1), the *average* PASP seems quite high to me. When I do echo for evaluation of SOB, and see RV enlargement *and* PASP over 60, I tend to think “chronic” and would ask for more… Read more »
Agree. These pts are milder than I would normally consider lysis in. They seemed to enter more based on clot size/density than bad signs. I think this is why they called them “moderate” rather than sub-massive as the latter requires the echo/marker signs of heart dysfunction. You would know better than I whether PASP can differentiate chronic vs. acute. I have always looked at RV wall thickness as my arbiter.
Agreed. Free RV wall thickness, regional wall motion abnormalities as in McConnells sign and TAPSE can all be helpful. But if patients can´t be properly positioned, apical views are often not good especially free RV wall (I call it “The dark territory”). Subcostal view is often best.
But I think ist makes sense that without chronic cor pulmonale the RV will usually not manage to perform > 60 mmHg of PASP. Of course, patients with cor pulmonale can also have acute PE. I just wondered about the high number of pts with PAH in this group.
Great podcast. If I was having a moderate PE I would much prefer lysis. Gets rid of all that remaining DVT too and might help prevent post phlebitic syndrome in the limbs. I have always understood that there is a higher bleeding risk with lysing PE compared to coronary lysis, because when a clot is lysed the FDPs are themselves anticoagulant. This wouldn’t matter with a small clot such as you find inside coronary arteries, but when a large clot is lysed ie not just the PE but the whole remaining DVT in the leg, then this is probably a… Read more »
Based on Klines look at complications, even full dose has an extremely low complication rate. It is in stroke where we can do a lot of damage with tPA.
Well Goldhaber I think did full dose and didn’t get any bleeds in anyone under age 56yrs. (that was a very old article though that I read years ago), however I guess the risk is theoretical ie if a large clot when lysed does in fact anticoagulate one more from it’s FDPS (and I don’t recall where I read that) then it stands to reason you would choose a lesser dose.
Thanks for the Podcast. Great work.
Can you please clarify in your podcast the indications for inclusion in the study. ‘Moderate PE’ in the published article is based upon CT or VQ findings, whereas “RV enlargement or hypokinesia and elevation of biomarkers of RV injury (troponin I and brain natriuretic peptide), although measured, were not a requirement for enrollment”.
I find the VQ criteria weaker than the CT ones, and it would have been interesting to see how many patients were investigated by either modality. However, the results do seem to suggest a strong benefit with little harm.
Yeah, I thought that was weird as well. They went by PE size/location rather than markers of RV dysfunction, that’s why they use the weird name rather than submassive.
Wouldn’t it make sense to at least use location as one indicator for inclusion in the study as its based on the assumption that the lungs (and therefore the embolism) receive the complete cardiac output and thus are exposed to the entirety of the the t-PA (on first pass). If you included had small subsegmental clots, even if they resulted in RV strain, you could no longer assume that they would be receiving the entire lytic dose. A large segmental clot should theoretically be exposed to 1/5th of the pulmonary circulation (not accounting for gravitational flow of blood) and be… Read more »
Should read “if you included patients that had small subsegmental clots…”
Interesting theory. I think the tPA is actually going to be circulating many times around and should hit the clots where-ever they are, but I’m just postulating.